Biogen Inc. $BIIB Shares Purchased by USS Investment Management Ltd

USS Investment Management Ltd grew its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 8.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 37,217 shares of the biotechnology company’s stock after buying an additional 3,001 shares during the period. USS Investment Management Ltd’s holdings in Biogen were worth $6,822,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in BIIB. Reflection Asset Management purchased a new position in Biogen in the fourth quarter valued at approximately $25,000. WPG Advisers LLC boosted its holdings in shares of Biogen by 417.9% in the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 117 shares in the last quarter. First Horizon Corp purchased a new position in shares of Biogen in the 4th quarter valued at $30,000. WFA of San Diego LLC purchased a new position in shares of Biogen in the 2nd quarter valued at $32,000. Finally, Root Financial Partners LLC lifted its position in Biogen by 198.4% in the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 123 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Royal Bank Of Canada lifted their target price on Biogen from $222.00 to $227.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 27th. JPMorgan Chase & Co. boosted their price objective on Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a research note on Thursday, April 23rd. Canaccord Genuity Group increased their price objective on Biogen from $230.00 to $245.00 and gave the company a “buy” rating in a report on Wednesday, April 1st. Oppenheimer lifted their target price on shares of Biogen from $275.00 to $300.00 and gave the company an “outperform” rating in a report on Thursday, May 14th. Finally, Needham & Company LLC increased their price target on shares of Biogen from $255.00 to $256.00 and gave the stock a “buy” rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $217.41.

Biogen Stock Performance

Biogen stock opened at $216.12 on Friday. Biogen Inc. has a fifty-two week low of $121.05 and a fifty-two week high of $219.72. The company has a market capitalization of $31.91 billion, a price-to-earnings ratio of 23.19 and a beta of 0.16. The stock has a fifty day moving average of $196.09 and a two-hundred day moving average of $186.83. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the prior year, the firm posted $3.02 earnings per share. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, analysts anticipate that Biogen Inc. will post 13.95 EPS for the current fiscal year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.